Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accumulated Expenses (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Accumulated Expenses for 7 consecutive years, with $1.7 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Accumulated Expenses fell 64.93% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2019, down 64.93%, and an annual FY2018 reading of $4.3 million, up 91.16% over the prior year.
  • Accumulated Expenses was $1.7 million for Q3 2019 at Larimar Therapeutics, down from $3.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.9 million in Q3 2018 and bottomed at $543000.0 in Q1 2015.
  • Average Accumulated Expenses over 5 years is $2.4 million, with a median of $1.9 million recorded in 2015.
  • The sharpest move saw Accumulated Expenses plummeted 80.54% in 2015, then skyrocketed 297.61% in 2016.
  • Year by year, Accumulated Expenses stood at $1.8 million in 2015, then surged by 107.16% to $3.7 million in 2016, then plummeted by 40.29% to $2.2 million in 2017, then surged by 91.16% to $4.3 million in 2018, then crashed by 59.66% to $1.7 million in 2019.
  • Business Quant data shows Accumulated Expenses for LRMR at $1.7 million in Q3 2019, $3.5 million in Q2 2019, and $931000.0 in Q1 2019.